Abstract

In this issue of Blood, Amengual et al report the results of a single-institution dose-escalation phase 1 study of pralatrexate plus romidepsin for patients with relapsed/refractory non-Hodgkin lymphoma. This combination resulted in a very high response rate in patients with previously treated peripheral T-cell lymphoma (PTCL) 1 .

Original languageEnglish (US)
Pages (from-to)375-376
Number of pages2
JournalBlood
Volume131
Issue number4
DOIs
StatePublished - Jan 25 2018

    Fingerprint

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this